AzTrials
AzTrials

Chronic Kidney DiseaseExPANDNCT06243068

Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial

A study testing Educate and Engage and Educate and Engage Plus Kidney Supportive Care Program in people with Chronic Kidney Disease, run by George Washington University at 25 sites in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to compare two health system-based approaches for offering kidney failure treatment options to older patients with kidney failure, specifically, to ensure patients are actively involved in a shared decision making (SDM) process covering a full range of treatment choices and have… Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Chronic Kidney Disease
What is being tested?
Educate and Engage and Educate and Engage Plus Kidney Supportive Care Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,000 participants
Where
25 sitesUnited States
Study dates
13 Nov 2024to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Age 65 years or older
  • Most recent eGFR <30 at time of screening AND meets practice site criteria for KDE referral
  • Treatment naïve (no dialysis or kidney transplant prior to enrollment)
  • Family member or care partner of Population 1 patient who has chosen active medical care without dialysis and consented to decisional conflict surveys
  • 18+ years old
  • English or Spanish speaking
Show all 9Show fewer
  • Cognitively able to participate in surveys/interviews
  • Study Population 3: Administrator, clinical provider, or staff at participating chronic kidney disease clinic
  • Currently practicing or employed at participating clinic

Who cannot join

  • The current decrease in eGFR is thought to be due to an acute event.
  • Education and initiation of shared decision-making process are not yet indicated for the patient, (per practice protocol and/or provider's judgment).
  • Insufficient decision-making capacity
  • Non-English and non-Spanish speaking
  • Treating nephrologist/APP opts patient out (for example, if contraindicated for patient's health)
  • Study Population 2: Family member or care partner of patient in Study Population 1

Trial locations and contacts

25 sites in 1 country. Contact the study team or a site near you to ask about taking part.

25 sites in 1 country

United States25 sites
  • Virginia Nephrology Group

    Alexandria, Virginia, 22304

  • Virginia Nephrology Group

    Arlington, Virginia, 22205

  • Southeast Kidney Associates

    Canton, Georgia, 30114

  • Renal Disease Research Institute

    Dallas, Texas, 75246

  • Southeast Kidney Associates

    East Point, Georgia, 30344

  • Clinical Renal Associates

    Exton, Pennsylvania, 19341

  • Virginia Nephrology Group

    Fairfax, Virginia, 22030

  • West Virginia University Medicine

    Fairmont, West Virginia, 26554

  • Renal Disease Research Institute

    Fort Worth, Texas, 76104

  • Renal Disease Research Institute

    Garland, Texas, 75044

  • Renal Disease Research Institute

    Irving, Texas, 75061

  • North Texas Kidney Disease Associates

    Lewisville, Texas, 75057

  • Renal Disease Research Institute

    McKinney, Texas, 75069

  • Renal Disease Research Institute

    McKinney, Texas, 75071

  • Renal Disease Research Institute

    Mesquite, Texas, 75150

  • West Virginia University Medicine

    Morgantown, West Virginia, 26506

  • The Rogosin Institute Manhattan Eat Dialysis

    New York, New York, 10021

  • North Texas Kidney Disease Associates

    North Richland Hills, Texas, 76180

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania, 19104

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, 19104

  • North Texas Kidney Disease Associates

    Plano, Texas, 75093

  • Renal Disease Research Institute

    Plano, Texas, 75093

  • UCSF/Zuckerberg San Francisco General Hospital and Trauma Center-Nephrology

    San Francisco, California, 94110

  • St. Clair Nephrology

    Shelby, Michigan, 48315

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia, 20010

Other trials in United States

About this study

Official title: Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People With Kidney Disease (The ExPAND Trial)

The goal of this clinical trial is to compare two health system-based approaches for offering kidney failure treatment options to older patients with kidney failure, specifically, to ensure patients are actively involved in a shared decision making (SDM) process covering a full range of treatment choices and have meaningful access to that full range of choices. These include standard in-center or home dialysis as well as alternative treatment plans (ATPs): active medical care without dialysis, time-limited trial of dialysis, and palliative dialysis.

Approach 1 - Educate and Engage:

Read more

Nephrology practices encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in SDM with staff trained in communication skills and best practices.

Approach 2 - Educate and Engage Plus Kidney Supportive Care Program:

Nephrology practices add a primary palliative care program to support patients who choose ATPs and their families. The program provides care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist.

To compare the two approaches, the investigators will conduct a repeated, cross-sectional stepped wedge cluster randomized trial involving 14 chronic kidney disease clinics at 7 practice organizations around the United States.

Aim 1: Compare the effectiveness of Approaches 1 and 2 in increasing proportion of patients choosing ATP and explore comparative effectiveness on patient reported outcomes of decisional conflict and shared decision-making as well as health care utilization and advance care planning.

Aim 2: Compare the patient and family experience of ATP care between Approaches 1 and 2 in terms of quality of life, services used, and end of life (EOL) experience. Aim 2a will focus on experience while patients are receiving an ATP. Aim 2b will describe the EOL experience.

Aim 3: Evaluate implementation of each approach through a mixed-methods design based on the expanded RE-AIM framework.

For Aims 1 and 2, researchers will collect information by chart review, surveys, and interviews with patients and care partners. For Aim 3, clinic administrators, clinical providers, and staff will complete pre- and post-test surveys at the beginning and end of each training.

Read the detailed description

Detailed Description

Background: Over 130,000 patients with kidney failure start dialysis annually. Older patients constitute the fastest growing segment. Those who are frail or have other serious medical conditions may not live any longer with dialysis than without it. US healthcare policy has created a powerful "dialysis default," where virtually all patients with kidney failure who do not receive a transplant are treated with a standard dialysis regimen in a dialysis center regardless of whether it will help them live any longer or better. About 20% of patients regret the decision to start dialysis, yet non-dialysis alternatives are rarely offered to them. Most patients report they were unaware they had a choice about kidney failure treatment. Many older patients with kidney disease value independence over staying alive longer. Not aware of their patients' values, most nephrologists do not offer alternatives to standard dialysis such as active medical care without dialysis (AMCWD), a time-limited trial of dialysis (TLT), and palliative dialysis.

Similarly, these options, which the investigators have collectively labeled alternative treatment plans (ATPs), are rarely included in kidney disease education (KDE) sessions for patients funded by Medicare. Other countries-notably Australia, Canada, and the United Kingdom-have found that about 15% of older patients with kidney failure prefer AMCWD. These countries have created programs within their healthcare systems that integrate primary palliative care into care for patients who choose an ATP. These programs report excellent outcomes in terms of patient quality of life, care according to patient's wishes, and patient survival on average for over a year. These programs have shown it is possible to avoid complications at the end of life such as patients who wanted AMCWD being started on dialysis because their symptoms were not well managed. These programs provide an extra layer of support and prepare patients and families for when the patient's kidney failure worsens.

Shared decision-making (SDM) is recognized as the preferred approach to implementing patient-centered care and assuring that patients receive treatment that matches their goals. For over a decade, SDM has been recommended by nephrology professional societies before initiating dialysis. Despite the recommendation and preference for SDM of people with advanced chronic kidney disease (CKD), it remains poorly implemented, and observers have noted a powerful dialysis default with few perceived alternatives. There is an urgent need for strategies to increase adoption and implementation of SDM in nephrology practices and elsewhere in healthcare systems where CKD patients receive care.

Objective: The goal of this clinical trial is to compare two health system-based approaches (interventions) for offering kidney failure treatment options to older patients with kidney failure. Specifically, the goal is to ensure patients with kidney failure are actively involved in a SDM process covering a full range of treatment choices and have meaningful access to that full range of choices. These include standard in-center or home dialysis as well as alternative treatment plans: active medical management without dialysis (AMCWD), time-limited trial of dialysis (TLT), and palliative dialysis.

Interventions - Approach 1: Educate and Engage:

In this approach, nephrology practices implement a bundle in which the participants will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.

Interventions - Approach 2: Educate and Engage Plus Kidney Supportive Care Program:

In this approach, nephrology practices continue to implement the Educate and Engage bundle and additionally, offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist.

Study Design: To compare the two approaches, the investigators will conduct a repeated, cross-sectional stepped wedge cluster randomized trial (SW-CRT) involving 14 chronic kidney disease clinics at 7 practice organizations around the United States. Participating clinical sites will be randomly placed into one of three sequences. Each sequence consists of four 10-month time periods during which patients are accrued and followed for study outcomes. All practices begin by implementing Approach 1 (Educate and Engage). Practices then add Approach 2 (Kidney Supportive Care Program) at the assigned period based on their sequence. To minimize contamination in the primary analysis, we will exclude patients recruited during the 4 months before each sequence moves to Approach 2. These patients will be included in a sensitivity analysis. In the 4th study period, accrual of new patients will stop during a 4-month follow-up period (to collect primary outcomes) at the end of the study. Patients will receive the intervention based on the approach (condition) in which the site is enrolled at the time of accrual. When a practice site begins implementation of Approach 2, referral to the kidney supportive care program for patients considering ATPs will become standard care at that site. All patients still alive who chose ATPs in prior periods will be offered the option of receiving care from the newly organized supportive care program.

In addition to the primary SW-CRT comparing the two intervention approaches, the investigators will do a pre-post comparison of primary outcomes, comparing clinic practices at baseline with each of the interventions.

Research Aims:

Aim 1: Compare the effectiveness of two approaches: 1) improved kidney disease education (KDE) and SDM or 2) improved KDE and SDM plus the creation of a kidney supportive care program in increasing proportion of patients choosing ATP and explore comparative effectiveness on patient reported outcomes of decisional conflict and shared decision-making as well as health care utilization and advance care planning.

Aim 2: Compare the patient and family experience of an ATP between Approach 1 and Approach 2 in terms of quality of life, services used, and end of life (EOL) experience through medical record review and interviews with a sample of patients, family members, and care partners. Aim 2a will focus on experience while patients are receiving an ATP (several months to several years). Aim 2b will describe the EOL experience.

Aim 3: Evaluate implementation of each intervention (Approaches 1 and 2) through a mixed-methods design based on the expanded RE-AIM framework, which integrates the Implementation Outcomes Framework by positing that the implementation outcomes acceptability (whether interventions are agreeable and satisfactory), appropriateness (perceived fit, relevance, and compatibility), and feasibility (extent to which interventions can be used successfully) are predictors of successful adoption, implementation, and maintenance. The ExPAND research team will cooperate with a separate tandem evaluation conducted by an independent evaluation team based at NORC.

Study Activities and Data Collection for Aim 1

  • Patients 65 years of age or older will be enrolled when their eGFR drops below 30.
  • Patients are invited to take a series of three surveys that include the Decision Conflict Scale and other assessments. The baseline survey (DCS-1) is taken at the time of enrollment. Follow-up surveys are conducted at Month 4 and Month 9 after enrollment.
  • The research coordinator (RC) conducts a chart audit to look for advance care planning documentation and current treatment preference 4 months after enrollment.

Study Activities and Data Collection for Aim 2 - Patients who choose an AMCWD

  • The RC conducts a quarterly chart audit for each patient who chooses active medical care without dialysis. The audit assesses the number of clinic visits, hospitalizations, changes in treatment plans, and unplanned dialysis starts.
  • A small open cohort of AMCWD patients and their family members/care partners are invited to participate in a longitudinal series of interviews about their experience of care under an AMCWD, starting at the time of treatment decision and continuing every 4 months until the end of the study or death of the patient.
  • For AMCWD patients who die, the RC conducts a chart review to assess EOL service utilization and advance care planning.
  • A purposeful sample of family members/care partners of AMCWD patients are invited to participate in bereavement interviews 4 months after patient death.

Study Activities and Data Collection for Aim 3

  • Clinic administrators, clinicians, and staff are invited to participate in pre-and post-test surveys at beginning and end of training.
Being tested
Educate and Engage, Educate and Engage Plus Kidney Supportive Care Program
Keywords
CKD, Alternative Treatment Plan, KDE, Kidney Disease Education, Palliative Care, Shared-Decision Making, Active Medical Management without Dialysis, AMCWD, Kidney Supportive Care, ESRD
Medical subject headings
Renal Insufficiency, Chronic, Kidney Failure, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Educate and EngageBehavioural

    Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.

  • Educate and Engage Plus Kidney Supportive Care ProgramBehavioural

    In addition to bundle described under "Educate and Engage," nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist.

Study groups in NCT06243068
Study groupRoleWhat they receive
Educate and EngageExperimentalPatients accrued and making treatment decisions while the clinic treating them is implementing Approach 1.
Receives: Behavioral: Educate and Engage
Educate and Engage Plus Kidney Supportive Care ProgramExperimentalPatients accrued and making treatment decisions while the clinic treating them is implementing Approach 2.
Receives: Behavioral: Educate and Engage Plus Kidney Supportive Care Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients choosing Alternative Treatment Plans (ATP)

    Numerator: number of patients choosing an alternative treatment plan. Denominator: enrolled patients with decision-making capacity.

    Measured: Month 4 after enrollment.

Secondary outcomes (5)
  1. Decisional Conflict Scale score

    Decisional Conflict Scale (O'Connor, 1995) score at month 4 survey, adjusted for baseline score. Score ranges from 0 (no decisional conflict) to 100 (extremely high decisional conflict).

    Measured: Month 4 after enrollment.

  2. Rating of CKD Knowledge Among Older Adults (Know-CKD) score

    Rating of CKD Knowledge Among Older Adults (Know-CKD) 4 months after initiation of treatment decision-making process. Decision-Aid for Renal Therapy (DART) Knowledge Assessment (Ladin et al., 2023). The DART survey contains 10 items scored on a 3 point scale, with 0 points given for an answer of yes, 2 for an answer of unsure, and 4 for an answer of no. The total score is the sum of the 10 items, multiplied by 2.5. The minimum score possible is 0 (no decisional conflict) and the maximum score possible is 100 (extremely high decisional conflict) (Month three score, adjusted for baseline score)

    Measured: Four months after enrollment.

  3. Shared Decision Making Questionnaire (SDM-Q-9) score

    9-Item Shared Decision Making Questionnaire (SDM-Q-9) score (Scholl, 2010). Score ranges from 0 (least SDM) to 45 (most SDM).

    Measured: Month 4 after enrollment.

  4. CollaboRATE score

    CollaboRATE score (Elwyn et al., 2013). Scores range from 0 (least SDM) to 9 (most SDM).

    Measured: Month 4 after enrollment.

  5. Advance care planning (ACP) documentation

    Complete ACP measure (Three elements present in chart: a surrogate, a goals of care discussion, and either an accessible advance directive or medical order such as POLST or DNR.)

    Measured: Month 4 after enrollment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2024
  2. Study start13 Nov 2024
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
We will use a repeated cross-sectional stepped wedge design with randomization at the practice level.
Masking
None (open label)
Enrolment
3,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06243068
Sponsor's protocol ID
NCR235148
Other IDs
IHS-2022C2-27678
Acronym
ExPAND
Status last verified
Jun 2026
First submitted
20 Dec 2023
Last updated
11 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After completion of the study, the completely deidentified research data from this project will be deposited with the digital repository, the Patient-Centered Outcomes Data Repository (PCODR), of the Inter-university Consortium for Political and Social Research (ICPSR), University of Michigan to ensure that the research community has long-term access to the data. This is required by PCORI and included in consent forms.

Publications

  • Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med. 1997 Jan;11(1):3-20. doi: 10.1177/026921639701100102.

    PubMed 9068681
  • Engelberg R, Downey L, Curtis JR. Psychometric characteristics of a quality of communication questionnaire assessing communication about end-of-life care. J Palliat Med. 2006 Oct;9(5):1086-98. doi: 10.1089/jpm.2006.9.1086.

    PubMed 17040146
  • Ladin K, Tighiouart H, Bronzi O, Koch-Weser S, Wong JB, Levine S, Agarwal A, Ren L, Degnan J, Sewall LN, Kuramitsu B, Fox P, Gordon EJ, Isakova T, Rifkin D, Rossi A, Weiner DE. Effectiveness of an Intervention to Improve Decision Making for Older Patients With Advanced Chronic Kidney Disease : A Randomized Controlled Trial. Ann Intern Med. 2023 Jan;176(1):29-38. doi: 10.7326/M22-1543. Epub 2022 Dec 20.

    PubMed 36534976
  • Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. Patient Educ Couns. 2013 Oct;93(1):102-7. doi: 10.1016/j.pec.2013.05.009. Epub 2013 Jun 12.

    PubMed 23768763
  • Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.

    PubMed 16129869
  • Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010 Feb;5(2):195-204. doi: 10.2215/CJN.05960809. Epub 2010 Jan 14.

    PubMed 20089488
  • Reilly KL, Kennedy S, Porter G, Estabrooks P. Comparing, Contrasting, and Integrating Dissemination and Implementation Outcomes Included in the RE-AIM and Implementation Outcomes Frameworks. Front Public Health. 2020 Sep 2;8:430. doi: 10.3389/fpubh.2020.00430. eCollection 2020.

    PubMed 32984239
  • Wong SPY, McFarland LV, Liu CF, Laundry RJ, Hebert PL, O'Hare AM. Care Practices for Patients With Advanced Kidney Disease Who Forgo Maintenance Dialysis. JAMA Intern Med. 2019 Mar 1;179(3):305-313. doi: 10.1001/jamainternmed.2018.6197.

    PubMed 30667475
  • Morton RL, Tong A, Howard K, Snelling P, Webster AC. The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. BMJ. 2010 Jan 19;340:c112. doi: 10.1136/bmj.c112.

    PubMed 20085970
  • Murtagh FEM, Burns A, Moranne O, Morton RL, Naicker S. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1909-1914. doi: 10.2215/CJN.04840516. Epub 2016 Aug 10.

    PubMed 27510453
  • Saeed F, Ladwig SA, Epstein RM, Monk RD, Duberstein PR. Dialysis Regret: Prevalence and Correlates. Clin J Am Soc Nephrol. 2020 Jul 1;15(7):957-963. doi: 10.2215/CJN.13781119. Epub 2020 Jun 4.

    PubMed 32499230
  • Chandna SM, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K. Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. Nephrol Dial Transplant. 2011 May;26(5):1608-14. doi: 10.1093/ndt/gfq630. Epub 2010 Nov 22.

    PubMed 21098012
  • USRDS. USRDS Annual Data Report USRDS Annual Data Report. Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities, United States Renal Data System. 2018. 42.

  • Gale RC, Wu J, Erhardt T, Bounthavong M, Reardon CM, Damschroder LJ, Midboe AM. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019 Feb 1;14(1):11. doi: 10.1186/s13012-019-0853-y.

    PubMed 30709368
  • Rhodes T, Stimson GV, Fitch C, Ball A, Renton A. Rapid assessment, injecting drug use, and public health. Lancet. 1999 Jul 3;354(9172):65-8. doi: 10.1016/S0140-6736(98)07612-0. No abstract available.

    PubMed 10406380

Questions about this trial

What is this clinical trial studying?

A study testing Educate and Engage and Educate and Engage Plus Kidney Supportive Care Program in people with Chronic Kidney Disease, run by George Washington University at 25 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients choosing Alternative Treatment Plans (ATP) (time frame: Month 4 after enrollment.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06243068, which also lists 33 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in